Research Insights
Evidence-based analysis of peptide research. Research digests unpack landmark studies; trend reports surface cross-peptide patterns; evidence briefs deliver fast reads on single questions.
Monthly GLP-1 Injections: What's in Development, When They'll Arrive, and Whether Switching From Weekly Is Worth It
Amgen's MariTide, Pfizer's MET-097i, and several other monthly GLP-1 candidates are working through late-stage trials. This piece walks through why manufacturers are chasing monthly dosing, which candidates are in development, the real convenience-versus-efficacy trade-offs, and how to think about switching once monthly options reach the market in 2027-2028.
How Much Muscle You Lose on Ozempic, Wegovy, and Zepbound — and What to Do About It
About one-quarter to one-third of the weight people lose on GLP-1 drugs comes from lean tissue rather than fat. Enveda's Phase 1 pill ENV-308 is one of several drugs designed to change that ratio. This piece walks through the muscle-loss data, why it matters for metabolism and function, what's in development to address it, and what current users can do right now.
TrumpRx and the January 2026 GLP-1 Price Cut: A Buyer's Guide to $245 Wegovy, $149 Pills, and Real Out-of-Pocket Costs
The November 2025 pricing agreement between the Trump administration and Eli Lilly plus Novo Nordisk cuts GLP-1 prices for Medicare, Medicaid, and direct-to-consumer purchases starting January 2026. This piece walks through the price you pay under each type of coverage, when the changes take effect, how TrumpRx works, and what compounded-GLP-1 users should be thinking about.
Muscle Preservation on GLP-1s: What UCN2, Amylin, and GIP Add for Body Recomp
Body recomposition means losing fat while keeping (or gaining) muscle. GLP-1 monotherapy is the wrong tool for that on its own — semaglutide and Wegovy lose roughly 25% of total weight as lean mass, and some patients lose more. This piece walks through the muscle-loss problem, what each next-generation mechanism adds (GIP, amylin, glucagon, UCN2), and what a body-recomp protocol on a GLP-1 actually looks like in practice.
Glutathione IV Drips, Oral Pills, and Injections: The Bioavailability Gap Between Formats
Glutathione is one of the most-sold wellness peptides in the US. You can buy it as pills on Amazon, as an IV drip at a medspa, or as an injectable vial from a compounding pharmacy. The problem: how much of it actually reaches your bloodstream depends heavily on which format you choose. This piece walks through what glutathione is, why bioavailability matters here, and how each format compares.
Real-World Weight Loss on Ozempic and Wegovy: The 5-12% You Might Get Versus the 15% in the Trials
Semaglutide's registrational trial (STEP-1) reported 14.9% mean weight loss at 68 weeks. Real-world registry and claims analyses report 5.9% to 12% at 6 to 12 months for the same drug in the same doses. This piece walks through what the trials measured, what real-world data shows, why the gap exists, who tends to respond better, and what a buyer can actually expect.
Wegovy 7.2 mg: The Higher-Dose Semaglutide Under FDA Review at Roughly 19% Weight Loss
Novo Nordisk has a higher-dose version of Wegovy under FDA review. Semaglutide 7.2 mg once weekly (up from the currently-approved 2.4 mg maximum) produced roughly 19% weight loss in the Phase 3 STEP UP trial, versus roughly 15% for the current 2.4 mg dose. This piece walks through what STEP UP showed, where the FDA review stands, how tolerability changes at higher doses, and how Wegovy 7.2 mg compares to Zepbound and retatrutide for current Wegovy users considering an intensification.
Retatrutide 28.7% and Ribupatide 23.6%: The Triple-Agonist Obesity Race Heading Into 2027
Two obesity drugs now hit three receptors at once — GLP-1, GIP, and glucagon. Eli Lilly's retatrutide filed the highest weight-loss number ever recorded in a Phase 3 trial. Kailera and Hengrui's ribupatide is behind but coming with an oral formulation. This piece walks through what a triple agonist is, why the third receptor matters, where the trials stand, and how the race is likely to play out into 2027 and 2028.
Setmelanotide (IMCIVREE) and Melanotan II: Same Peptide Family, Different Regulatory Worlds
One is an FDA-approved rare-disease drug that recorded 400 patient starts in six weeks. The other is a gray-market tanning peptide that regulators in Australia, the UK, and the EU tell people to avoid. Both are made from almost the same starting parts. This piece walks through the two molecules in plain language and uses the story to explain how a molecule becomes an approved drug in the first place.
CagriSema Lost to Tirzepatide by 2.5 Percentage Points at 84 Weeks. The Amylin Bet Didn't Pay Off.
Novo Nordisk's REDEFINE 4 trial pitted CagriSema (cagrilintide plus semaglutide) against Eli Lilly's tirzepatide over 84 weeks. CagriSema reached 23.0% weight loss. Tirzepatide reached 25.5%. The primary non-inferiority endpoint missed. This piece walks through the two mechanisms, why the GIP add-on beat the amylin add-on in this setup, what that says about retatrutide's triple agonist, and where it leaves CagriSema's commercial path.
Melanotan II Goes to the FDA Advisory Panel in February 2027
The FDA's Pharmacy Compounding Advisory Committee will review melanotan II in February 2027 for possible inclusion on the Section 503A bulks list. Melanotan II is currently sold gray-market as a tanning peptide and appetite suppressant. This piece walks through what the peptide is, what the safety record looks like, why regulators in other countries have warned against it, and what the FDA vote would actually change.
Arrowhead Paid $215 Million for a Priority Review Voucher. The Return Math Depends on Three Things.
In August 2026, Arrowhead Pharmaceuticals disclosed it paid $215 million for a Priority Review Voucher to shorten its plozasiran severe hypertriglyceridemia review from ten months to six. Management projects a 3x return. This piece walks through what a PRV is, where the secondary market has priced them, why Arrowhead thought this one worth the price, and when the math actually works for a buyer.
The Compounded Tirzepatide Problem: The B12 Chemistry Study Found Novel Molecules in the Vials
A 2026 chemistry study documented that compounded tirzepatide combined with vitamin B12 can chemically bond and form a new molecule that does not exist in the FDA-approved Zepbound or Mounjaro. Vitamin B12 is the most common additive that compounding pharmacies use to distinguish their products from the Eli Lilly branded tirzepatide. That distinction matters. This piece explains what compounding pharmacies do with B12 in these formulations, what the chemistry study found, why the FDA cited findings of this kind in its July 30, 2026 rulemaking to permanently exclude the branded GLP-1 molecules from the Section 503B Bulks List, and what patients on compounded tirzepatide should think about right now.
Fatigue on GLP-1s: The Fixes That Move the Needle on Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo
Extreme tiredness is one of the most common complaints from people on GLP-1 receptor agonist therapy: Ozempic (semaglutide), Wegovy (semaglutide, injection or pill), Mounjaro (tirzepatide), Zepbound (tirzepatide), Rybelsus (oral semaglutide), Foundayo (orforglipron), Trulicity (dulaglutide), and Saxenda (liraglutide). The fatigue is usually not random. It has specific mechanistic causes and a set of evidence-based interventions that most patients can work through with their prescriber. This piece walks through why GLP-1 receptor agonists cause fatigue, how to rule out red flags, what nutrition, training, hydration, and sleep changes actually help, and what to think about peptides that get marketed for energy and recovery in the wellness channel.
The GLP-1 Eye-Safety Signal: NAION Cases Cluster Around Semaglutide, Not Tirzepatide
On July 25, 2026, Australia's Therapeutics Goods Administration (TGA) updated the labels of every GLP-1 receptor agonist sold in the country with a new warning about non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. The TGA Advisory Committee on Medicines reached a specific conclusion: current evidence supports the signal for semaglutide (Ozempic, Wegovy), but not for dulaglutide (Trulicity) or tirzepatide (Mounjaro). This piece explains what NAION is, what the Australian action actually says, how the drug-specific split came out of the data, and what patients on GLP-1 therapy should know.
The Oral GLP-1 Landscape Is a Three-Horse Race: Foundayo (Orforglipron), the Wegovy Pill (Oral Semaglutide), and AstraZeneca's Elecoglipron (Phase 3 Just Launched)
For most of the GLP-1 era, oral GLP-1 meant one thing: Novo Nordisk's Rybelsus (oral semaglutide, launched 2019) for type 2 diabetes. That changed in 2025-2026. Novo launched the Wegovy pill (oral semaglutide 25 mg / 50 mg for obesity) in Q1 2026 after OASIS 4 met its endpoints. Eli Lilly received FDA approval of Foundayo (orforglipron), the first small-molecule oral GLP-1 receptor agonist, in April 2026. And on Monday July 27, 2026, AstraZeneca confirmed on its Q2 2026 earnings call that elecoglipron, the oral small-molecule GLP-1 that AstraZeneca licensed from Shanghai-based Eccogene, has moved into a full Phase 3 program across the EMBOLD (obesity) and ELUMINATE (type 2 diabetes) trials plus cardiovascular and kidney outcomes studies. This piece walks through what the three oral GLP-1 options look like today, what the head-to-head data shows, and how patients should think about the choice.
Teens on GLP-1s: Bariatric Surgery Down Three-Fold, GLP-1 Monotherapy Now 96% of Adolescent Obesity Treatment (JAMA Pediatrics)
On July 20, 2026, JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study analyzing 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. The headline finding: the share of patients using only GLP-1 receptor agonist drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026), while the share of patients undergoing metabolic and bariatric surgery (MBS) fell from 11.6% to 3.7%. This piece walks through what the study actually measured, what the trend means for families making decisions today, what the study doesn't answer, and questions parents and teens should bring to a pediatric or adolescent-medicine appointment.
The FDA Panel Voted Yes on BPC-157 and KPV. Compounding Is Still Not Legal Today.
On July 23, 2026, an FDA advisory committee voted 8-6 with one abstention to recommend adding BPC-157 to the Section 503A compounding list. Later the same day, the panel voted identically to recommend KPV. Coverage all afternoon suggested peptides are now legal to prescribe. They aren't. This piece explains what the vote actually does, what still has to happen at the FDA, and when the real timeline for changed access lands.
The First Oral PCSK9 Inhibitor Just Got Approved. LIPFENDRA (Enlicitide) Sits Next to Your Statin, Not in Place of It.
On July 16, 2026, the FDA approved Merck's LIPFENDRA (enlicitide), the first once-daily oral pill in a drug class that had been injection-only since 2015. The drug is a macrocyclic peptide that survives your stomach and gets absorbed intact. It lowered LDL cholesterol by 56-59% in two Phase 3 trials. Merck priced it at $315 per month, roughly one-third the cost of the injectable competitors. This piece walks through what PCSK9 is, why oral matters, and what to think about if you or someone you know is on a statin.
IgA Nephropathy Got Two New Drugs in Ten Days. Trutakna and Fabhalta Do Different Things to Different Targets.
Vera Therapeutics' Trutakna won FDA approval on July 7, 2026. Novartis's Fabhalta won a full FDA approval on July 17. Both treat the same rare kidney disease that affects roughly 140,000 Americans. They work through very different biology and measure success against different endpoints. This piece walks through what each drug does, what the trial data actually showed, and what to ask a kidney doctor if either might be an option for you.
Medicare Launched GLP-1 Coverage. Your Employer Probably Still Won't Cover It.
The Medicare GLP-1 Bridge started July 1, 2026. Novo Nordisk cut prices. Employer coverage of GLP-1s for weight loss still sits at 36%, the same as last year. This piece walks through the numbers, the reasons, and what it means if you are on a GLP-1 or want to start.
Who's Really Selling Your Peptides? What Chainalysis Traced in the Gray Market
Blockchain analysts followed the crypto payments US buyers send to online peptide vendors. Some of those wallets used to sell fentanyl precursors. In the first three months of 2026 alone, $27 million in gray-market peptide crypto moved through a network that partly overlaps with the illegal drug trade. Here is what that means for anyone buying peptides online.
China's GLP-1 Export Machine: How the Obesity Pipeline's Biggest Deals Now Start in China
Positive obesity-pill data out of China on July 7 was one data point in a larger shift. A third of global drug-licensing dollars in early 2025 chased Chinese molecules, and obesity is the hottest category.
Beyond the Weekly Shot: The Race to Put GLP-1s in Implants and Patches
A twice-yearly semaglutide implant and a needle-free weekly patch both took real steps forward in mid-2026. The history of this exact idea says the device is the hard part.
The BPC-157 Analog Development Race: Fixing the Half-Life Problem Before It Reaches the FDA
Original BPC-157 clears the blood in under 30 minutes and has no completed Phase 2 trial after 30 years of research. Several biotechs are racing to build BPC-157 analogs with longer half-lives, better absorption, and the human safety data that would win FDA approval. Here is who's working on what.
Generic Tirzepatide: When Will Zepbound Get Cheaper?
Sandoz filed the first US application for generic Mounjaro and Zepbound. The FDA accepted the applications on June 29, 2026. Approval takes 12 to 24 months, and Lilly's patents run until 2036 or later. Here is what that means for prices at the pharmacy counter, the Medicare Bridge, and the broader GLP-1 market.
The 2026 Peptide Telehealth Landscape: Hims, LifeMD, Henry Meds, Ro, Pep Club, NohoLabs, and How to Pick
Half a dozen online platforms now prescribe and ship peptides to your door. They look similar on the outside. Under the hood, they source from different pharmacies, offer different peptides, charge different prices, and handle quality control very differently. Here is what each one actually does, and how to choose.
The FDA's Briefing Documents on Each of the Seven Peptides Going to PCAC
Career-staff scientists concluded ahead of the July 23-24 vote that none of the seven substances (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) has sufficient evidence for the 503A bulks list. Here is what the briefing actually says about each one, what FDA tested in compounded product samples, and where the strongest and weakest cases sit.
The PCAC Panelist Conflicts Map: Who FDA Named Monday and What They Sell
FDA published the names of eight new Pharmacy Compounding Advisory Committee panelists on Monday June 29. At least seven of the eight have ties to peptide-related businesses and clinics. Here is what the named members do for a living, what FDA conflict-of-interest rules require, and how this panel composition compares to previous PCAC reviews.
The Medicare GLP-1 Bridge: A Patient Guide to the July 1, 2026 Launch
Eligible Part D beneficiaries pay $50/month for Foundayo, Wegovy (injection or tablet), or Zepbound KwikPen through December 31, 2027. Here is who qualifies, how to apply through your doctor and pharmacy via Humana, what is covered, and what is not.
The AI Peptide Drug-Discovery Deal Map: Where the 2026 Capital Is Flowing
Six anchor deals from November 2025 through June 2026 totaled more than $9 billion in committed-and-contingent value. Chai-Lilly, Parabilis-Regeneron, Unnatural Products-Novartis, Insilico-SK Biopharm, Biogen-Dayra, Pinnacle Series B. Here's what each company actually does, and what the deal flow says about the next twelve months.
How to Evaluate a Compounding Pharmacy: 503A vs 503B, USP Standards, COAs, and What to Ask
If PCAC opens the door for BPC-157, TB-500, KPV, MOTS-c, and friends on July 23-24, prescription compounding becomes the legal supply path. Here is how to tell a real pharmacy from a research-chemical site in a lab coat: the regulatory tiers that matter, the USP standards that govern preparation, what a real Certificate of Analysis looks like, and the questions a good pharmacy will answer without flinching.
The July 23-24 PCAC Peptide Vote, Explained: What Happens to BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon
Seven peptides go to a Pharmacy Compounding Advisory Committee vote four weeks from now. The FDA's final call follows the vote but does not have to follow it. Here's what each peptide is, what the evidence looks like, and what 'yes' and 'no' mean for compounding pharmacies, Hims & Hers, and the gray market.
Compassionate Use and Obesity Drugs: What the Retatrutide Mystery-Patient Case Reveals
FDA grants 1,800+ expanded-access requests a year and approves 99% of them. Almost none are for obesity. The June 2026 retatrutide case is the rare exception, and the political fallout is louder than the precedent.
Best Peptides for Wrinkles: The Shelf and the Trials Behind It
Matrixyl, Matrixyl 3000, copper peptides, and Argireline dominate the wrinkle-peptide category. The marketing numbers and the published trial numbers don't always line up. This piece covers both.
Peptides for Spinal Cord Injury and Stroke Recovery: Phase 3, Gray Market, and the Evidence Map
NervGen NVG-291 heads to Phase 3 in chronic tetraplegia mid-2026. Cerebrolysin: 50-country approval, no US. BPC-157 and TB-500 forum threads outrun the data.
Peptides for Dogs: The Veterinary Evidence for BPC-157, TB-500, and Cerenia
Forum claims for BPC-157 and TB-500 in senior dogs run ahead of the data. Zoetis Librela and Cytopoint are the real veterinary peptide success stories.
Peptides for Erectile Dysfunction and Male Sexual Health: PT-141, Vyleesi, and the Evidence Map
PT-141 (bremelanotide) is FDA-approved for women, used off-label in men. Melanotan II shares the receptors with worse safety. The honest evidence map.
Peptides for Lower Back Pain: BPC-157, TB-500, and the Evidence Map
BPC-157 and TB-500 dominate the forum claims. Lilly's retatrutide chronic low back pain Phase 3 is the strongest evidence anyone has. Here's the honest map.
What Happens If Your Job Drops GLP-1 Coverage in 2027
A June 2026 survey found 1 in 10 large employers plan to stop covering Wegovy, Zepbound, and Foundayo next year. Here's the price map if that includes you.
Weight Loss Drugs and Bone Health: The New Fracture and BMD Data
Doctors worried weight loss from Ozempic and Wegovy would weaken bones. A new Stanford study tracking 161 million patients found the opposite.
What Doctors Are Learning About GLP-1s and Male Fertility
Men on Ozempic and Wegovy have been asking about testosterone and sperm. New ENDO 2026 data reverses what most people feared.
The Race to Bring Back a Hormone Most People Have Never Heard Of
PTH keeps blood calcium steady. At ENDO 2026 in Chicago, three peptide companies (Ascendis, MBX, Entera Bio) showed three different ways to replace it.
The Two Worlds of GHK-Cu: How a $32 Serum and a Restricted Injectable Are the Same Molecule
Cosmetic GHK-Cu sells freely at Ulta. Injectable GHK-Cu sits in FDA limbo ahead of a 2027 PCAC vote. The split is regulatory, not chemical.
Monthly GLP-1: Why Pfizer, Amgen, and Ascletis Are Stretching the Dose Interval
Two thirds of weekly GLP-1 patients quit within a year. The race to a monthly injection is a bet that adherence, not efficacy, decides the next decade.
The Amylin Wave: How a Forgotten Diabetes Hormone Became Obesity's Second Pillar
Pramlintide flopped in 2005. Forty amylin programs and $19B in deals have now turned the class into the GI-tolerant counterweight to GLP-1.
Ozempic for Kidney Disease: What the FLOW Trial Changed
Semaglutide became the first GLP-1 approved for chronic kidney disease in January 2025. What the FLOW trial showed, what the label covers, what's still open.
GLP-1s and Surgery: When to Stop Ozempic Before Anesthesia, and Why the Rule Changed
The 2023 advice was simple: stop the drug. By 2024 the major societies reversed it. Here is what the evidence actually shows and what to do before a procedure.
GLP-1s, Pregnancy, and Birth Control: The 'Ozempic Babies' Guide
Why surprise pregnancies happen on these drugs, the tirzepatide-pill interaction that semaglutide does not share, and how long to stop before trying to conceive.
May 2026 in Peptides: TRIUMPH-1, the Maintenance Pivot, and the First HDV Drug
Retatrutide's 28.3% ceiling, Novo's oral GLP-1 lead, ECO's maintenance pivot, EASL MASH and HBV-cure data, and bulevirtide's first HDV approval.
Microdosing Ozempic: The Reddit Trend, the Off-Label Doses, and the Missing Evidence
Sub-label GLP-1 dosing went from Reddit to a Rebel Wilson ad in eighteen months. The evidence is thin, the pharmacology unfriendly, and the real story is compounding.
Which MASH Drug for Which Patient: A Plain-English Guide for 2026
Two years ago there were zero approved drugs for MASH, the serious form of fatty liver disease. Now there are two — Rezdiffra and semaglutide (Wegovy) — and a wave of others is close behind. EASL 2026 in Barcelona this week brought fresh data on most of them: survodutide in the NEJM, pemvidutide's 48-week results, Aligos and Akero and the rest. Here's a plain-English guide to what's available, what's coming, and how doctors are starting to match the right drug to the right patient.
Beyond GLP-1 Alone: Why Combination Therapy Is the Next Obesity Breakthrough
Single-drug GLP-1 therapy hit a ceiling at about 28-30% weight loss with retatrutide. The next jump probably won't come from another solo drug. It'll come from pairing GLP-1s with other mechanisms. EASL 2026 in Barcelona gave the strongest evidence yet: Arrowhead's experimental RNAi drug ARO-INHBE doubled weight loss and tripled fat reduction when added to a small dose of tirzepatide. Here's why combination therapy is becoming the next frontier in obesity and MASH, and what's coming.
GLP-1s and Cancer: The 2026 Evidence Map Across Colorectal, Pancreatic, Breast, and Thyroid
Roughly 30 million Americans are now on GLP-1 therapy, and the cancer angle of that drug class has shifted meaningfully over the past two years. ASCO 2026 Abstract 3143, previewed today, documented 38-50% lower metastatic progression across four obesity-related cancers in 12,112 patients. A 2025 ASCO observational study found a 7% lower incidence of fourteen obesity-related cancers in 170,000+ GLP-1 users versus DPP-4 inhibitor patients. The MTC and pancreatic cancer warnings haven't borne out in human data. Here's what the cancer evidence actually shows, where the signal is strongest, where the methodology gets soft, and how to think about the cancer angle if you're already on or considering GLP-1 therapy.
GLP-1s vs Bariatric Surgery: How to Think About the Choice in 2026
Bariatric surgery procedures dropped below 200,000 in 2024 — the first time since 2020 — as GLP-1 prescriptions grew from 4,600 in 2018 to 1.4 million in 2025. Wegovy 14.9%, Zepbound 22.5%, Wegovy HD 20.7%, and retatrutide 28.3% now overlap substantially with sleeve gastrectomy (25-30%) and Roux-en-Y gastric bypass (30-35%). Here's what the comparison actually shows, where surgery still wins, where pharmacology now wins, and how to think about your own decision.
The Dysesthesia Signal: Why Retatrutide Tingles, and the Nerve-Fiber Question Behind It
About 20.9% of participants on retatrutide 12 mg reported dysesthesia in both the TRIUMPH-1 full ADA 2026 readout and the earlier TRIUMPH-4 trial — abnormal skin sensations that didn't appear in the tirzepatide or semaglutide development programs. The signal traces to retatrutide's third receptor arm: glucagon. Here's what the trial data showed, the most-likely mechanism, why the effect is dose-dependent, and how prescribers should think about it ahead of the 2027 approval window.
Should I Wait for Retatrutide? What TRIUMPH-1's 28.3% Phase 3 Readout Just Changed About Obesity Prescribing
Eli Lilly released TRIUMPH-1 Phase 3 topline May 21: retatrutide produced 28.3% mean weight loss at 12 mg over 80 weeks, 30.3% in the 104-week BMI ≥35 extension, and 45.3% of participants reached ≥30% weight loss — bariatric-surgery territory. The NDA filing is now Q4 2026 / Q1 2027, with TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + cardiovascular disease) still pending later this year. Here's what the readout means for patients deciding between starting Wegovy or Zepbound now and waiting for retatrutide.
GPR119 Agonists: The Indirect GLP-1 Strategy Pharma Is Trying Again
Sanofi paid $375M for the lead GPR119 agonist MBX-2982 in June 2010 and walked away by May 2011. The receptor is supposed to make your gut release its own GLP-1 — and fifteen years of failed development have made that simple idea quietly contentious. MetaVia's vanoglipel posted Phase 2a MASH data at AASLD in November 2025 and lands three late-breaking posters at ADA 2026 on June 7. Here's what GPR119 actually does, why the first wave of programs failed, and what's different this time.
NK2R: The Next Obesity Receptor After GLP-1?
Novo Nordisk paid €470M for an NK2R startup in 2023. The Nature paper landed in November 2024. Tsinghua's 2026 AI peptide design competition has now picked NK2R as the benchmark target. Here's what the receptor actually does, why it could avoid the nausea problem that limits GLP-1 adherence, and the realistic timeline to clinic.
$28/Year Generic Semaglutide Is Already Possible And It Won't Reach US Patients Until 2032
A March 2026 medRxiv preprint priced generic injectable semaglutide at $28-140/person-year, and Canada, India, and Brazil are already running with that math. US patent protection on the active drug runs through December 2031. The catch isn't manufacturing — it's device patents, policy coordination, and Novo's preemptive 2027 list-price cut.
EASO First-Line: The New Obesity Treatment Algorithm by Complication, Explained
The European Association for the Study of Obesity published an updated treatment framework in Nature Medicine on May 14, 2026, formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications. The choice between them is no longer 'whichever your insurance covers' — it now depends on which complications you have.
GLP-1s After 65: Efficacy, Muscle Loss, and Cardiovascular Outcomes in the New Data
Two ECO 2026 senior-population analyses — Padova's STEP pool on semaglutide 2.4 mg and Lilly's ATTAIN pool on orforglipron — finally fill a clinical gap that's existed since Wegovy launched. Here's how to read them, where the data still falls short, and what it means for prescribing in adults over 65.
How to Stay Off GLP-1s: The 2026 Maintenance Playbook
The May 12 SURMOUNT-MAINTAIN (Lancet) and ATTAIN-MAINTAIN (Nature Medicine) dual publication finally gives prescribers Phase 3 evidence for what happens when patients step down from injectable GLP-1s. Spoiler: with the right protocol, most of the weight loss stays. Without it, two-thirds comes back.
Wegovy Across Menopause: The May 2026 Data for Women in Their 40s and 50s
A new STEP UP post-hoc analysis and a 34,000-woman real-world database, both presented at ECO 2026, finally answer the question many perimenopausal women have been asking: does this drug work the same way during the hormonal transition? Plus a SELECT subgroup result on cardiovascular events that's bigger than the population average.
Beyond Weight Loss: 8 Non-GLP-1 Peptides Tackling Rare Disease in 2026
While the obesity drugs eat the headlines, a second-tier pipeline of peptide therapeutics is doing real work in indications most patients have never heard of. Post-bariatric hypoglycemia, hypothalamic obesity, oral PTH for osteoporosis, oligonucleotide conjugates for DM1. Here's what's actually in the clinic and what the next 18 months look like.
AI-Designed Cyclic Peptides Are Cracking Undruggable Targets
In the last four weeks: CIP-3 hit nanomolar CD28 antagonism from an AI design pipeline, CycloSEL screened 16 million macrocycles to nail a WDR5 inhibitor, Merck published a biocatalytic synthesis that cuts oral PCSK9 step count by more than half. The cyclic-peptide drug-discovery stack just changed. Here's what's actually new.
Tired on a GLP-1? Why Retatrutide Hits Harder and What Helps
Fatigue affects 5–11% of GLP-1 users in trials — Ozempic, Wegovy, Mounjaro, Zepbound included — and retatrutide's glucagon-receptor activity gives it a different fatigue profile from the rest. Here's what's mechanism, what's calorie deficit, and what's a sourcing problem in disguise.
What's Next After GLP-1: 6 Peptide-Receptor Systems Driving the Next Decade of Obesity Drugs
An April 10, 2026 Frontiers in Drug Discovery review and a companion Bloomgarden commentary in Journal of Diabetes have laid out the post-incretin research agenda. The candidates: apelin, spexin, phoenixin, relaxin-3, osteocalcin, irisin. Plus Stanford's BRP and a few others. Here's what's actually credible.
Tweaked Your Back? Tore Something Snowboarding? What Peptides Can and Can't Do for Injury Recovery
BPC-157, TB-500, and the Wolverine Stack get pitched as a recovery cheat code. The animal data is real, the human evidence is thinner than the marketing suggests, and the regulatory ground keeps moving.
Peptide Blends vs. Separate Vials: KLOW, Glow, and Wolverine Without the Marketing
A blend is cheaper per milligram and easier to reconstitute. It also locks your ratio, hides which component caused the welt, and has zero published stability data. When the blend math works, when it doesn't, and what experienced users actually do.
April 2026 in Peptides: The Month That Reset the Industry
Foundayo's launch, the FDA Category 2 removal, Lilly's $19.8B quarter, AACR peptide oncology, and a 503B compounding proposal all in 30 days.
Peptides vs. Growth Hormone (HGH): Why the Pituitary Pathway Isn't the Same as Direct Injection
Sermorelin, CJC-1295, ipamorelin, tesamorelin, MK-677 push your pituitary to release GH. Recombinant HGH skips it entirely — that gap drives the differences.
CGRP and Migraine: The Peptide Drug Class Most Peptide-Curious People Have Never Heard Of
Eight FDA-approved drugs target the CGRP peptide. Anti-CGRP antibodies halve monthly migraine days for 30-49% of patients — peptide drug class most fans miss.
Peptides for Sleep: The RCT Evidence on DSIP, Epitalon, and Semax
MK-677 boosts slow-wave sleep 50%. Three orexin antagonists are FDA-approved. DSIP — the peptide literally named for sleep — has almost no modern data.
Peptides for Gaining Weight: Lean Mass, Appetite, and the Underweight Patient
Peptides for weight gain in the underweight, post-illness, and post-GLP-1 patient: the appetite and IGF-1 effects others call side effects are the mechanism.
Blood Work Before and After Peptides: The Panels That Show Whether Yours Is Working
A peptide-by-peptide guide to blood work, body comp scans, and questionnaires that make a subjective protocol measurable: IGF-1, HOMA-IR, DEXA, CD4:CD8, PHQ-9.
Peptides for Anxiety, Panic, and Stress: Where the Evidence Lands
Selank has RCT data vs. benzos. Oxytocin can paradoxically raise anxiety. GLP-1s show big anxiolytic signals in observational data — state of the 2026 evidence.
Peptides for Chronic Gut Issues: IBD, IBS, Leaky Gut, and the Evidence Hierarchy
Four peptides are FDA-approved for gut conditions. BPC-157 — the one everyone asks about — has a Phase 2 UC trial that was completed and never published.
Peptides for Fertility and IVF: The Clinical Evidence in 2026
Modern IVF runs on peptides. GnRH analogs power every cycle, and kisspeptin triggers may eliminate OHSS risk for high-risk patients. State of the field in 2026.
Peptides for Long COVID, ME/CFS, and Post-Viral Fatigue: The Evidence Map
Clinics prescribe peptides for post-viral fatigue. NIH RECOVER doesn't. The gap between peptide rationale and evidence is wider than the marketing suggests.
Peptides for MCAS and POTS: The Mast Cell and Autonomic Cluster
MCAS and POTS co-occur in 66% of cases. Best peptide signal: a 47-patient GLP-1 series. Some peptides release histamine and flare what you're treating.
Peptide-Drug Conjugates: The Quiet Revolution in Targeted Cancer Therapy
Two FDA-approved drugs, 50+ in trials, and a $1.5B market by 2031 — PDCs are finally having their moment.
The Muscle-Preservation Race: Trevogrumab, Bimagrumab, Apitegromab, and the Pharmacology of Keeping Lean Mass on GLP-1s
About a third of GLP-1-induced weight loss is lean mass. Four drugs targeting the myostatin/activin pathway are now in obesity trials. COURAGE, BELIEVE, and EMBRAZE have produced the first Phase 2 readouts. What the data shows, how the mechanisms differ, and why the FDA is raising the bar.
Peptides for Acne-Prone and Post-Acne Skin: The Evidence Map
Antimicrobial peptides kill Cutibacterium acnes in preclinical studies — but the real clinical wins for peptides in acne are on the aftermath: post-inflammatory hyperpigmentation, scar remodeling, and barrier repair. Here's the honest breakdown of mechanism vs. clinical evidence.
Peptides for Arthritis: What Actually Works, What's Still Preclinical, and What the Hype Gets Wrong
GLP-1 knee-osteoarthritis data is the strongest peptide-arthritis evidence in 2026. PEPITEM matched infliximab in mice. BPC-157 and TB-500 have one retrospective study between them. The peptide-for-arthritis story, mapped against the clinical evidence.
Eating Enough Protein — and Training Hard Enough — on GLP-1s
A San Raffaele study tracking 332 adults found that GLP-1 users consume just 0.6 g/kg/day of protein — 88% fall below even conservative guidelines. The muscle-loss data, the protein math, and why resistance training isn't optional.
The CJC-1295/Ipamorelin Flush: Why Your Face Gets Hot After the Shot
Ipamorelin was engineered specifically to eliminate the systemic flush that plagued GHRP-6. So why do users on the CJC/Ipamorelin blend still get warm-faced, tingly, and lightheaded? The answer points squarely at the DAC.
GHK-Cu Stinging and Welts: The Copper Peptide Side Effect Most Users Experience
It's not an allergy and it's not a bad batch — it's copper chemistry. Why GHK-Cu is the outlier among peptides, what's happening under your skin, and the dilution-plus-timing fix that actually works.
Why So Many People Quit GLP-1 Drugs — And How to Stay on Track
Fewer than 1 in 4 patients stay on GLP-1 medications after a year, and two-thirds of lost weight comes back after stopping. Here's what the data says about why people quit, what happens when they do, and practical strategies for sticking with it.
Tanning Peptides: Melanotan I vs Melanotan II Across Efficacy, Safety, and Regulatory Status
One is FDA-approved with 1,000+ patients and zero melanomas. The other is an unlicensed TikTok trend linked to melanoma case reports. They share a name and a receptor — but almost nothing else.
Transitioning From Semaglutide/Tirzepatide to Retatrutide: The Data, the Reddit Reports, and the Dosing Gaps Between Them
Retatrutide is a reset, not a continuation. Here's what the Phase 3 evidence, pharmacology, and community transition patterns say about sequencing the triple agonist after semaglutide or tirzepatide.
GLP-1 Drugs and Addiction: Can Ozempic Curb Alcohol, Opioids, and More?
A landmark study of 606,000 veterans found GLP-1 drugs reduced new substance use disorders by 14-25% and overdose deaths by 50%. From alcohol to opioids to cannabis, the reward-pathway science is catching up to what patients have been reporting for years.
When Do GLP-1 Patents Expire? The Complete Generic Timeline
Semaglutide patents are already expiring outside the US, generic liraglutide launched in 2025, and tirzepatide is locked up until 2036. Here's when each GLP-1 drug becomes available as a generic — and what that means for cost.
Peptides and Sports: Which Ones Will Get You Banned
From CrossFit to UFC, athletes are catching multi-year bans for peptides like BPC-157, CJC-1295, and TB-500. Here's exactly what WADA prohibits, who's been caught, and what competitive athletes need to know.
The Peptide Quality Crisis: What Investigations Found and How to Protect Yourself
Within two weeks in April 2026, ProPublica, The New Yorker, The Guardian, NBC News, and regulators in three countries reached the same conclusion: a lot of what people are injecting isn't what's on the label.
Peptides and the Menstrual Cycle: Timing, Side Effects, and Hormonal Interactions
GLP-1 nausea is worse when estrogen peaks. GH secretagogue response varies by cycle phase. Kisspeptin sensitivity shifts across the month. Here's what the science says about how peptides interact with the menstrual cycle.
The Peptide Skin-Brightening Lineup: Glutathione, Nonapeptide-1, Oligopeptide-68, and Decapeptide-12
Hydroquinone, kojic acid, and arbutin dominate the hyperpigmentation market — but a new generation of peptides targets melanin synthesis at four different points in the pathway, often with far better safety profiles. Here's what the clinical evidence actually shows for each.
Looksmaxxing Peptides: The Evidence Behind the Aesthetic Optimization Trend
From Retatrutide body recomposition to GHK-Cu skin protocols, peptide stacks have become the backbone of the looksmaxxing movement. We break down what the science actually supports — and where the hype runs ahead of the data.
Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro
GLP-1 drugs work — but muscle loss, GI distress, and skin laxity have people adding BPC-157, GH secretagogues, and more. Here's what the stacking rationale looks like, and where the evidence actually is.
Peptides for Running, Cardio, and Endurance: Recovery, Performance, and the Evidence Map
From BPC-157 for tendon injuries to MOTS-c for mitochondrial performance, runners are turning to peptides for an edge. Here's what actually has data behind it — and what's still a bet on animal studies.
Foundayo vs Oral Wegovy: The Battle of the GLP-1 Pills
Eli Lilly's small-molecule pill vs Novo Nordisk's peptide tablet. One is more convenient, the other more effective. Here's what the data shows — and why no head-to-head trial exists yet.
Peptide Injection Site Reactions: Histamine, Mast Cells, and What's Normal
That red, itchy welt after your CJC-1295/Ipamorelin shot isn't an allergy — it's mast cell degranulation, and some peptides trigger it far more than others. Here's the science, the spectrum, and when to actually worry.
Oral vs Injectable Peptides: Foundayo's Approval Reshapes the Delivery Debate
Eli Lilly's oral GLP-1 pill eliminates injections entirely. Here's how oral and injectable peptide delivery compare — and why the future of peptide therapy may be swallowed, not injected.
The Most Popular Peptides of 2026
From oral GLP-1 pills and triple agonists to the FDA reclassification saga and a copper peptide going viral — what's driving 10 million monthly peptide searches.
Will Peptides Work for Me? What Genetics, Sex, and Phenotype Tell Us
A landmark 2026 Nature study of 27,885 people found genetic variants that predict GLP-1 drug response. But genetics is just one piece — here's the full picture of why peptides work differently for different people.
Weight Loss Peptides and Muscle Loss: The Problem, the Science, and How to Protect Lean Mass
GLP-1 drugs produce dramatic fat loss — but 25-40% of weight lost is muscle. New combinations like bimagrumab + semaglutide and next-gen drugs like retatrutide may change that equation.
GLP-1 Drugs and Emotional Flattening: What We Know and Don't Know
Reports of reduced libido, emotional blunting, and 'falling out of love' on semaglutide and retatrutide are growing. The neuroscience is plausible — but the clinical evidence is still early.
Supplements That Stack Well with Peptides: An Evidence-Based Guide
From creatine for GLP-1 muscle preservation to zinc for thymic peptides and magnesium for sleep-stack GH protocols — what the research supports.
Peptide Legality in 2026: FDA Status, Compounding, and the RFK Reclassification
The regulatory landscape for peptides is shifting fast. Here's what's actually changed, what's still pending, and how to legally access peptide therapy in 2026.
Ozempic Alternatives in 2026: Compounded Semaglutide, New Drugs, and What to Know
Brand-name GLP-1 drugs cost $1,000+/month. Here's a research-backed look at compounded semaglutide, tirzepatide, oral options, and what's coming next.
Peptides for Women: The Research Across Menopause, Fertility, Skin, and Bone
From FDA-approved sexual health treatments to weight loss, skincare, and fertility — a research-backed look at which peptides have been studied in women and what the evidence says.
Best Peptides for Muscle Growth: The 2026 Evidence Map
GH secretagogues, IGF-1 variants, and recovery peptides can support lean mass — but the effects are modest compared to steroids. Here's the honest breakdown.
Peptides vs Steroids: A Complete Comparison
Peptides and anabolic steroids are fundamentally different — in mechanism, safety, legality, and what they can realistically achieve. Here's what the evidence shows.
Peptides for Hair Growth: GHK-Cu, TB-500, and the Research Behind Them
Copper peptides lead the evidence for peptide-based hair regrowth. Here's what's proven, what's promising, and what's hype.
LL-37 and the Antimicrobial Peptide Frontier
As antibiotic resistance grows, host defense peptides like LL-37 are being studied as a fundamentally different approach to fighting infection.
BPC-157 and Gut Healing: 30+ Studies, One Research Group, Three Human Trials
The most-cited peptide in the Atlas has a mountain of preclinical data. We break down what's proven, what's promising, and what's still missing.
The Evidence Gap: Which Popular Peptides Have Almost No Human Data?
A frank look at the disconnect between online popularity and clinical evidence for some of the most popular peptides.
GLP-1 Agonists Beyond Weight Loss
What 100+ clinical trials reveal about semaglutide, tirzepatide, and the next generation of incretin therapies — from cardiovascular protection to neurodegeneration.
The Mitochondrial Peptide Revolution
MOTS-c, SS-31, and Humanin are rewriting our understanding of aging at the cellular level. Here's what the research actually shows.
MK-677: The Oral Growth Hormone Secretagogue With 15 RCTs
One of the most studied non-injectable peptide mimetics — what the clinical trial evidence shows about sleep, muscle, bone, and the IGF-1 axis.
Neuropeptides in 2026: The State of Research Across CGRP, Oxytocin, Substance P, and Orexin
Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.
Tesamorelin: From HIV Lipodystrophy to Liver Health and Cognitive Enhancement
How a growth hormone-releasing peptide with 20+ RCTs became one of the most evidence-backed peptides in clinical medicine.
Thymic Peptides and Immune Restoration
Thymosin Alpha-1, Thymalin, and Thymulin — how thymus-derived peptides are being studied to combat immunosenescence and age-related immune decline.